Products
Platform
Research
Market
Learn
Compare UTI Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.25 | 1.87 |
NAV | ₹292.75 | ₹40.33 |
Fund Started | 01 Aug 2005 | 25 Jun 2018 |
Fund Size | ₹1096.95 Cr | ₹6226.82 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.25
1.87
NAV
₹292.75
₹40.33
Fund Started
01 Aug 2005
25 Jun 2018
Fund Size
₹1096.95 Cr
₹6226.82 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 0.80% | 2.62% |
3 Year | 24.88% | 28.00% |
5 Year | 17.55% | 20.28% |
1 Year
0.80%
2.62%
3 Year
24.88%
28.00%
5 Year
17.55%
20.28%
Holding Analysis
Equity | 98.98% | 97.55% |
Cash | 1.02% | 2.45% |
Equity
98.98%
97.55%
Cash
1.02%
2.45%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.61% |
Ajanta Pharma Ltd. | 5.48% |
Cipla Ltd. | 5.48% |
Lupin Ltd. | 4.70% |
Procter & Gamble Health Ltd. | 3.99% |
Glenmark Pharmaceuticals Ltd. | 3.74% |
Dr. Reddy's Laboratories Ltd. | 3.74% |
Gland Pharma Ltd. | 3.62% |
Apollo Hospitals Enterprise Ltd. | 3.58% |
Alkem Laboratories Ltd. | 3.56% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Fund Manager
Name | Kamal Gada | Dharmesh Kakkad |
Start Date | 02 May 2022 | 23 Feb 2021 |
Name
Kamal Gada
Dharmesh Kakkad
Start Date
02 May 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 01 Aug 2005 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
01 Aug 2005
25 Jun 2018